E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
SB-681323 is under development as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To determine the safety and tolerability of SB-681323 administered for 28 days in subjects with CHD on statin therapy. • To estimate the effect of 7.5 mg PO (5mg am, 2.5 mg pm) of SB-681323, compared to placebo, in reducing the acute increase in hsCRP observed following PCI in subjects with angiographically documented CHD.
|
|
E.2.2 | Secondary objectives of the trial |
• To characterise the chronic effect of 7.5 mg PO (5mg am, 2.5 mg pm) of SB-681323, compared to placebo, on stable hsCRP after 28 days of administration. • To evaluate the chronic effect of 7.5 mg PO (5mg am, 2.5 mg pm) of SB-681323, compared to placebo, on the array of soluble biomarkers. • To evaluate the effect of 7.5 mg PO (5mg am, 2.5 mg pm) of SB-681323, compared to placebo, on endothelial function utilizing peripheral arterial tonometry. • To evaluate the pharmacokinetics of 7.5 mg PO (5mg am, 2.5 mg pm) of SB-681323 in subjects under going elective PCI.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
A subject will be eligible for inclusion in this study only if all of the following criteria apply:
1. Male adults or female adults of non-child-bearing potential aged 18 to 80 years of age at screening. 2. Female Subjects included must have a negative pregnancy test (i.e. serum beta hCG test) and must be of non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is surgically sterile via hysterectomy or bilateral ligation or who is post-menopausal. For the purposes of this study, postmenopausal is defined as one year without menses). 3. Subjects who are scheduled to undergo elective single vessel PCI to be performed within the 6 weeks of diagnostic coronary angiography confirming obstructive CHD. 4. Subjects must have been on a stable dose of a statin for ≥ 6 weeks prior to screening, with statin tolerability and LDL <130 mg/dL (3.4 mmol/L) at the Screen visit. 5. Subjects capable of providing signed written informed consent to participate. 6. Subjects with a hsCRP concentration of >2 mg/L, but < 10 mg/L at screening.
|
|
E.4 | Principal exclusion criteria |
A subject will not be eligible for inclusion in this study if any of the following criteria apply: 1. Women who are pregnant or breast feeding. 2. Planned PCI with multi-vessel stenting. 3. Planned PCI with additional revascularization procedures staged at different days during the study period. 4. Planned PCI other than stenting (e.g., rotational atherectomy, direct atherectomy, balloon angioplasty without stenting, etc). 5. Planned PCI of any bypass graft. 6. History of CABG surgery. 7. Planned cardiac surgery (e.g., CABG, valve repair or replacement) or planned major non-cardiac surgery within the study period. 8. Disabling stroke in the past 6 months. 9. History of chronic viral hepatitis (including presence of hepatitis B surface antigen or hepatitis C antibody), or other chronic hepatic disorders. 10. History of Gilbert's syndrome or elevated bilirubin concentrations. Subjects with a total bilirubin concentration above the upper limit of normal at Screening will be excluded. 11. History of increased liver function tests (ALT, AST) due to acute or chronic liver conditions, above the upper limit of normal in the past 6 months and/or liver function tests (bilirubin, ALT, AST) above the upper limit of normal at Screening. 12. Renal impairment with serum creatinine >2.0 mg/dl (177umol/L) at Screening, or history of kidney transplant, or a history of contrast nephropathy. 13. Current inadequately controlled hypertension (blood pressure >160 mmHg systolic and/or >100 mmHg diastolic) on a stable dose of antihypertensive medication. 14. Current poorly controlled diabetes mellitus, defined as HbA1c >10% at Screen. 15. History of severe heart failure defined as NYHA class III or IV or those with known severe LV dysfunction (EF<30%) regardless of symptomatic status. 16. History of malignancy within the past 5 years, other than non-melanoma skin cancer. 17. Current life-threatening condition other than vascular disease (e.g., very severe chronic airways disease, HIV positive, life-threatening arrhythmias) that may prevent a subject from completing the study. 18. Alcohol or drug abuse within the past 6 months. 19. Previous exposure to SB-681323. 20. Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication. 21. Subjects who will commence or who are likely to commence treatment with oral intranasal or topical corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin, PPARγ agonists (e.g. rosiglitazone), fibrates, niacin from Screening until study completion. (Subjects who are receiving these medications at a stable dose at screening may be entered in the study.) 22. The patient has a three month prior history of alcohol use >2 units per day for males and >2 units per day for females or the patient has a positive alcohol screen at the screening visit. 23. Any other subject whom the Investigator deems unsuitable for the study (e.g., due to either medical reasons, laboratory abnormalities, expected study medication non-compliance, or subject’s unwillingness to comply with all study-related study procedures). 24. Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease). 25. Subjects with chronic infections such as gingivitis, periodontitis, prostatitis, gastritis, and urinary tract infections. 26. Subjects with any acute infection, symptoms suggestive of sinusitis, or significant trauma (burns, fractures). 27. A positive urine test for drugs of abuse (not related to known medications the subject is taking, ie, codeine for pain management) or alcohol at screening or prior to study medication administration. 28. Subjects who have donated more than 500 mL of blood within 56 days prior to the study medication administration. 29. Consumption of grapefruit or grapefruit juice within seven days prior to the first dose of study medication. 30. History of myopathy or rhabdomyolysis. 31. QTc interval >440 msec (males) or >450 msec (females).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Assessment of the incidence of liver function abnormalities (ALT) in conjunction with the other safety assessments based on the routine laboratory values including creatine kinase. • Baseline corrected hs-CRP concentrations at 2 days after PCI (i.e., 5 days on treatment).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |